

Supplemental Table 2. Age- and sex-specific prevalence (per 100 population) of the common drug groups 21 through 40 in the 2009 Olmsted County, MN, population (N= 142,377)

Drug group	Age (y) ^a										All ages		
	0-18		19-29		30-49		50-64		65+		Crude ^b		Standardized ^c %
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Genitourinary agents													
Both sexes	223	0.58	688	2.87	1,538	4.06	2,631	10.70	1,953	11.27	7,033	4.94	4.76
Men (boys)	51	0.26	68	0.66	590	3.30	1,250	10.87	868	11.52	2,827	4.23	4.22
Women (girls)	172	0.91	620	4.55	948	4.73	1,381	10.55	1,085	11.07	4,206	5.57	5.32
Thyroid modifiers													
Both sexes	94	0.24	346	1.44	1,792	4.72	2,132	8.67	2,180	12.57	6,544	4.60	4.52
Men (boys)	31	0.16	52	0.50	325	1.82	419	3.64	499	6.62	1,326	1.98	2.04
Women (girls)	63	0.33	294	2.16	1,467	7.32	1,713	13.08	1,681	17.15	5,218	6.91	6.72
Non-opioid analgesics													
Both sexes	573	1.49	513	2.14	1,451	3.83	1,638	6.66	2,076	11.98	6,251	4.39	4.36
Men (boys)	296	1.51	169	1.63	560	3.13	643	5.59	735	9.76	2,403	3.59	3.66
Women (girls)	277	1.46	344	2.52	891	4.45	995	7.60	1,341	13.68	3,848	5.10	4.96
Ophthalmic anti-infective/anti-inflammatory agents													
Both sexes	2,116	5.49	607	2.53	1,096	2.89	851	3.46	1,331	7.68	6,001	4.21	4.20
Men (boys)	1,069	5.45	199	1.93	463	2.59	346	3.01	540	7.17	2,617	3.91	3.90
Women (girls)	1,047	5.53	408	2.99	633	3.16	505	3.86	791	8.07	3,384	4.48	4.49

Supplemental Table 2. Continued

Drug group	Age (y) ^a										All ages		
	0-18		19-29		30-49		50-64		65+		Crude ^b		Standardized ^c
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Antitussives/expectorants													
Both sexes	455	1.18	870	3.63	2,013	5.31	1,456	5.92	1,024	5.91	5,818	4.09	4.04
Men (boys)	197	1.00	216	2.09	657	3.67	485	4.22	397	5.27	1,952	2.92	2.99
Women (girls)	258	1.36	654	4.80	1,356	6.77	971	7.42	627	6.40	3,866	5.12	5.05
Sulfonamide and related antimicrobials													
Both sexes	893	2.32	971	4.05	1,543	4.07	1,055	4.29	990	5.71	5,452	3.83	3.74
Men (boys)	228	1.16	141	1.36	300	1.68	270	2.35	274	3.64	1,213	1.81	1.83
Women (girls)	665	3.51	830	6.09	1,243	6.20	785	6.00	716	7.30	4,239	5.61	5.56
Antivirals													
Both sexes	1,456	3.78	857	3.58	1,640	4.32	995	4.05	467	2.69	5,415	3.80	3.76
Men (boys)	774	3.95	184	1.78	519	2.90	322	2.80	183	2.43	1,982	2.96	2.94
Women (girls)	682	3.60	673	4.94	1,121	5.59	673	5.14	284	2.90	3,433	4.55	4.55
Blood glucose regulation agents													
Both sexes	98	0.25	231	0.96	1,068	2.82	1,843	7.50	2,016	11.63	5,256	3.69	3.63
Men (boys)	51	0.26	78	0.75	529	2.96	995	8.66	1,036	13.75	2,689	4.02	4.08
Women (girls)	47	0.25	153	1.12	539	2.69	848	6.48	980	10.00	2,567	3.40	3.26

Supplemental Table 2. Continued

Drug group	Age (y) ^a										All ages		
	0-18		19-29		30-49		50-64		65+		Crude ^b		Standardized ^c
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Anti-acne agents													
Both sexes	1,598	4.14	1,270	5.30	1,216	3.21	691	2.81	323	1.86	5,098	3.58	3.47
Men (boys)	718	3.66	304	2.94	214	1.20	157	1.37	127	1.69	1,520	2.27	2.21
Women (girls)	880	4.64	966	7.09	1,002	5.00	534	4.08	196	2.00	3,578	4.74	4.71
Anticonvulsants													
Both sexes	333	0.86	580	2.42	1,607	4.24	1,328	5.40	1,101	6.35	4,949	3.48	3.46
Men (boys)	170	0.87	192	1.86	614	3.43	522	4.54	453	6.01	1,951	2.92	2.98
Women (girls)	163	0.86	388	2.85	993	4.96	806	6.16	648	6.61	2,998	3.97	3.91
Anti-infectives, other													
Both sexes	478	1.24	996	4.16	1,279	3.37	1,011	4.11	1,087	6.27	4,851	3.41	3.30
Men (boys)	167	0.85	142	1.37	321	1.79	397	3.45	449	5.96	1,476	2.21	2.24
Women (girls)	311	1.64	854	6.27	958	4.78	614	4.69	638	6.51	3,375	4.47	4.35
Hormones, other													
Both sexes	80	0.21	179	0.75	453	1.19	1,271	5.17	2,376	13.71	4,359	3.06	3.01
Men (boys)	59	0.30	31	0.30	149	0.83	267	2.32	574	7.62	1,080	1.62	1.67
Women (girls)	21	0.11	148	1.09	304	1.52	1,004	7.67	1,802	18.38	3,279	4.34	4.08

Supplemental Table 2. Continued

Drug group	Age (y) ^a										All ages		
	0-18		19-29		30-49		50-64		65+		Crude ^b		Standardized ^c
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Calcium channel blockers													
Both sexes	26	0.07	86	0.36	455	1.20	1,066	4.34	2,430	14.02	4,063	2.85	2.83
Men (boys)	12	0.06	20	0.19	204	1.14	527	4.58	904	12.00	1,667	2.49	2.57
Women (girls)	14	0.07	66	0.48	251	1.25	539	4.12	1,526	15.57	2,396	3.17	3.02
Tetracyclines													
Both sexes	612	1.59	811	3.38	1,062	2.80	618	2.51	520	3.00	3,623	2.54	2.51
Men (boys)	336	1.71	270	2.61	368	2.06	240	2.09	258	3.42	1,472	2.20	2.22
Women (girls)	276	1.46	541	3.97	694	3.46	378	2.89	262	2.67	2,151	2.85	2.81
Skeletal muscle relaxants													
Both sexes	51	0.13	612	2.55	1,624	4.28	905	3.68	368	2.12	3,560	2.50	2.51
Men (boys)	18	0.09	208	2.01	623	3.48	346	3.01	121	1.61	1,316	1.97	2.04
Women (girls)	33	0.17	404	2.96	1,001	5.00	559	4.27	247	2.52	2,244	2.97	2.97
Anticoagulants/antihemorrhagics/platelet aggregation inhibitors													
Both sexes	30	0.08	82	0.34	400	1.05	869	3.53	1,934	11.16	3,315	2.33	2.30
Men (boys)	14	0.07	30	0.29	211	1.18	539	4.69	1,020	13.54	1,814	2.71	2.80
Women (girls)	16	0.08	52	0.38	189	0.94	330	2.52	914	9.32	1,501	1.99	1.90

Supplemental Table 2. Continued

Drug group	Age (y) ^a										All ages		
	0-18		19-29		30-49		50-64		65+		Crude ^b		Standardized ^c
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Antifungals													
Both sexes	435	1.13	679	2.83	1,208	3.19	572	2.33	358	2.07	3,252	2.28	2.23
Men (boys)	194	0.99	64	0.62	162	0.91	150	1.30	116	1.54	686	1.03	1.02
Women (girls)	241	1.27	615	4.51	1,046	5.22	422	3.22	242	2.47	2,566	3.40	3.40
Antidotes, deterrents and poison control													
Both sexes	48	0.12	551	2.30	1,413	3.73	910	3.70	283	1.63	3,205	2.25	2.26
Men (boys)	26	0.13	201	1.94	655	3.66	444	3.86	130	1.73	1,456	2.18	2.23
Women (girls)	22	0.12	350	2.57	758	3.78	466	3.56	153	1.56	1,749	2.32	2.30
Central nervous system agents, other													
Both sexes	155	0.40	203	0.85	718	1.89	833	3.39	1,249	7.20	3,158	2.22	2.20
Men (boys)	93	0.47	68	0.66	263	1.47	281	2.44	481	6.39	1,186	1.77	1.83
Women (girls)	62	0.33	135	0.99	455	2.27	552	4.22	768	7.83	1,972	2.61	2.53
Dermatological agents, other													
Both sexes	515	1.34	419	1.75	878	2.31	633	2.57	580	3.35	3,025	2.12	2.10
Men (boys)	235	1.20	107	1.04	272	1.52	210	1.83	225	2.99	1,049	1.57	1.59
Women (girls)	280	1.48	312	2.29	606	3.02	423	3.23	355	3.62	1,976	2.62	2.60

Supplemental Table 2. Continued

^aNumbers indicate the actual number of cases observed. Prevalence can be computed by dividing the number of cases by the corresponding denominator listed below (and multiplying by 100)

Denominators for men (boys) and women (girls) combined: 0-18=38,558; 19-29=23,968; 30-49=37,927; 50-64=24,588; 65+=17,336

Denominators for men (boys): 0-18=19,611; 19-29=10,337; 30-49=17,888; 50-64=11,496; 65+=7533

Denominators for women (girls): 0-18=18,947; 19-29=13,631; 30-49=20,039; 50-64=13,092; 65+=9803

^bA crude prevalence was computed by dividing cases observed across all ages by the total population

^cOverall prevalence for men (boys) and women (girls) combined was standardized by age and sex; overall prevalence for men (boys) and women (girls) separately was standardized only by age (direct standardization using the 2000 US census population)